181 related articles for article (PubMed ID: 23291200)
1. Natural killer cell activity and function in chronic HCV-infected patients during peg interferon and ribavirin: early effects of active substance use.
Hotho DM; Kreefft K; Groothuismink ZM; Janssen HL; de Knegt RJ; Boonstra A
Antiviral Res; 2013 Mar; 97(3):347-55. PubMed ID: 23291200
[TBL] [Abstract][Full Text] [Related]
2. Increased proportion of the CD56(bright) NK cell subset in patients chronically infected with hepatitis C virus (HCV) receiving interferon-alpha and ribavirin therapy.
Lee S; Watson MW; Flexman JP; Cheng W; Hammond T; Price P
J Med Virol; 2010 Apr; 82(4):568-74. PubMed ID: 20166183
[TBL] [Abstract][Full Text] [Related]
3. Expansion of functionally skewed CD56-negative NK cells in chronic hepatitis C virus infection: correlation with outcome of pegylated IFN-alpha and ribavirin treatment.
Gonzalez VD; Falconer K; Björkström NK; Blom KG; Weiland O; Ljunggren HG; Alaeus A; Sandberg JK
J Immunol; 2009 Nov; 183(10):6612-8. PubMed ID: 19846870
[TBL] [Abstract][Full Text] [Related]
4. Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection.
Stegmann KA; Björkström NK; Veber H; Ciesek S; Riese P; Wiegand J; Hadem J; Suneetha PV; Jaroszewicz J; Wang C; Schlaphoff V; Fytili P; Cornberg M; Manns MP; Geffers R; Pietschmann T; Guzmán CA; Ljunggren HG; Wedemeyer H
Gastroenterology; 2010 May; 138(5):1885-97. PubMed ID: 20334827
[TBL] [Abstract][Full Text] [Related]
5. Chronic hepatitis C viral infection reduces NK cell frequency and suppresses cytokine secretion: Reversion by anti-viral treatment.
Dessouki O; Kamiya Y; Nagahama H; Tanaka M; Suzu S; Sasaki Y; Okada S
Biochem Biophys Res Commun; 2010 Mar; 393(2):331-7. PubMed ID: 20138830
[TBL] [Abstract][Full Text] [Related]
6. Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy.
Chuang WL; Dai CY; Chang WY; Lee LP; Lin ZY; Chen SC; Hsieh MY; Wang LY; Yu ML
Antivir Ther; 2005; 10(1):125-33. PubMed ID: 15751770
[TBL] [Abstract][Full Text] [Related]
7. [Alteration of CD100 expression on natural killer cells in chronic patients with hepatitis C virus before and after initiation of antiviral treatment].
He Y; Li B; Zhou Y; Zhang Y; Guo Y; Ji G; Fan C; Jia Z
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Aug; 30(8):856-60. PubMed ID: 25108441
[TBL] [Abstract][Full Text] [Related]
8. Early changes in interferon signaling define natural killer cell response and refractoriness to interferon-based therapy of hepatitis C patients.
Edlich B; Ahlenstiel G; Zabaleta Azpiroz A; Stoltzfus J; Noureddin M; Serti E; Feld JJ; Liang TJ; Rotman Y; Rehermann B
Hepatology; 2012 Jan; 55(1):39-48. PubMed ID: 21898483
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin.
Soriano V; Núñez M; Camino N; Maida I; Barreiro P; Romero M; Martin-Carbonero L; Garcia-Samaniego J; González-Lahoz J
Antivir Ther; 2004 Aug; 9(4):505-9. PubMed ID: 15456081
[TBL] [Abstract][Full Text] [Related]
10. CD56(+dim) and CD56(+bright) cell activation and apoptosis in hepatitis C virus infection.
Lin AW; Gonzalez SA; Cunningham-Rundles S; Dorante G; Marshall S; Tignor A; Ha C; Jacobson IM; Talal AH
Clin Exp Immunol; 2004 Aug; 137(2):408-16. PubMed ID: 15270860
[TBL] [Abstract][Full Text] [Related]
11. A potent antiviral effect on hepatitis C viral dynamics in serum and peripheral blood mononuclear cells during combination therapy with high-dose daily interferon alfa plus ribavirin and intravenous twice-daily treatment with interferon beta.
Asahina Y; Izumi N; Uchihara M; Noguchi O; Tsuchiya K; Hamano K; Kanazawa N; Itakura J; Miyake S; Sakai T
Hepatology; 2001 Aug; 34(2):377-84. PubMed ID: 11481623
[TBL] [Abstract][Full Text] [Related]
12. Altered interferon-alpha-signaling in natural killer cells from patients with chronic hepatitis C virus infection.
Miyagi T; Takehara T; Nishio K; Shimizu S; Kohga K; Li W; Tatsumi T; Hiramatsu N; Kanto T; Hayashi N
J Hepatol; 2010 Sep; 53(3):424-30. PubMed ID: 20554341
[TBL] [Abstract][Full Text] [Related]
13. Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules?
Schaefer M; Heinz A; Backmund M
Addiction; 2004 Sep; 99(9):1167-75. PubMed ID: 15317637
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal analysis of peripheral and intrahepatic NK cells in chronic HCV patients during antiviral therapy.
Spaan M; van Oord GW; Janssen HL; de Knegt RJ; Boonstra A
Antiviral Res; 2015 Nov; 123():86-92. PubMed ID: 26363298
[TBL] [Abstract][Full Text] [Related]
15. Altered natural killer cell subset distributions in resolved and persistent hepatitis C virus infection following single source exposure.
Golden-Mason L; Madrigal-Estebas L; McGrath E; Conroy MJ; Ryan EJ; Hegarty JE; O'Farrelly C; Doherty DG
Gut; 2008 Aug; 57(8):1121-8. PubMed ID: 18372499
[TBL] [Abstract][Full Text] [Related]
16. IL-26 is overexpressed in chronically HCV-infected patients and enhances TRAIL-mediated cytotoxicity and interferon production by human NK cells.
Miot C; Beaumont E; Duluc D; Le Guillou-Guillemette H; Preisser L; Garo E; Blanchard S; Hubert Fouchard I; Créminon C; Lamourette P; Fremaux I; Calès P; Lunel-Fabiani F; Boursier J; Braum O; Fickenscher H; Roingeard P; Delneste Y; Jeannin P
Gut; 2015 Sep; 64(9):1466-75. PubMed ID: 25183206
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover.
Zeuzem S; Schmidt JM; Lee JH; von Wagner M; Teuber G; Roth WK
Hepatology; 1998 Jul; 28(1):245-52. PubMed ID: 9657119
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis C testing and treatment among active drug users in Amsterdam: results from the DUTCH-C project.
Lindenburg CE; Lambers FA; Urbanus AT; Schinkel J; Jansen PL; Krol A; Casteelen G; van Santen G; van den Berg CH; Coutinho RA; Prins M; Weegink CJ
Eur J Gastroenterol Hepatol; 2011 Jan; 23(1):23-31. PubMed ID: 21042221
[TBL] [Abstract][Full Text] [Related]
19. Impaired ability of interferon-alpha-primed dendritic cells to stimulate Th1-type CD4 T-cell response in chronic hepatitis C virus infection.
Miyatake H; Kanto T; Inoue M; Sakakibara M; Kaimori A; Yakushijin T; Itose I; Miyazaki M; Kuzushita N; Hiramatsu N; Takehara T; Kasahara A; Hayashi N
J Viral Hepat; 2007 Jun; 14(6):404-12. PubMed ID: 17501761
[TBL] [Abstract][Full Text] [Related]
20. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy.
Yu ML; Chuang WL; Dai CY; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Tsai SL; Kuo HT
Transl Res; 2006 Sep; 148(3):120-7. PubMed ID: 16938649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]